阿戈美拉汀联合阿立哌唑治疗重度抑郁症的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect and safety of Agomelatine combined with Aripiprazole in the treatment of major depressive disorder. Methods A total of 62 patients with major depressive disorder admitted to our hospital from January to December 2019 were divided into observation group and control group with 31 cases in each group according to the random principle. The patients in both groups were given 25-50 mg/d Agomelatine and taken at night. On this basis, the patients in observation group were given Aripiprazole 10-15 mg/d in the morning; the patients in control group were given placebo with similar appearance, the dosage method was the same as Aripiprazole, and the treatment lasted for 6 weeks. The clinical effect, HAMD score and TESS were compared before treatment and at the 2nd,4th and 6th week of treatment. Results The effective rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant (P＜0.05). There was no statistically significant difference in the HAMD scores between the two groups before treatment (P＞0.05); the HAMD scores of the two groups at each time point after treatment were lower than those before treatment, and the differences were statistically significant (P＜0.05);the HAMD scores of 4 weeks and 6 weeks were lower than those of the control group, and the differences were statistically significant (P＜0.05). Adverse reactions include dizziness, headache, dizziness, insomnia, nausea, drowsiness, dry mouth, tachycardia, and transient liver function abnormalities, there was no statistically significant difference between the two groups of the incidence of adverse reactions (P＞0.05). Conclusion The combination of Agomelatine and Aripiprazole is more effective in the treatment of major depressive disorder, the improvement of symptoms is more obvious,and there is no significant increase in adverse reactions, which has positive clinical significance and is worth promoting.

Key words： Agomelatine Aripiprazole Severe Depression Adverse reactions

Received: 27 April 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/74

[1]	邓佳慧，李素霞，董问天，等.难治性抑郁症发病机制的研究进展[J].中国神经精神疾病杂志，2014，40（2）：123-125.
[2]	Kupfer DJ.Depression and associated sleep disturbances：patient benefits with Agomelatine[J].Europ Neuropsychopharmacol，2006，16（Supplement 4）：639-643.
[3]	Pandi-Perumal SR，Moscovitch A，Srinivasan V，et al.Bidirectional communication between sleep and circadian rhythms and its implications for depression：lessons from Agomelatine[J].Prog Neurobiol，2009，88（4）：264-271.
[4]	孙振晓，于相芬，孙波.睡眠障碍与抑郁症关系的研究进展[J].国际精神病学杂志，2008，35（2）：76-79.
[5]	洪武，司天梅，李凌江，等.阿戈美拉汀治疗抑郁症临床应用专家建议[J].中国新药与临床杂志，2018，37（11）：601-607.
[6]	Mohamed S，Johnson GR，Chen P，et al.Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment：the VAST-D randomized clinical trial[J].JAMA，2017，318（2）：132-145.
[7]	中华医学会精神科分会.中国精神疾病分类与诊断标准（CCMD-3）[M].3 版.济南：山东科学技术出版社，2001：75-78.
[8]	Nutt D.The hamilton depression Scale-accelerator or break on antidepressant drug discovery?[J].J Neurol Neurosurg Psychiatry，2014，85（2）：119-120.
[9]	张明园.副作用量表（TESS）[J].上海精神医学，1984，2：77-80.
[10]	陈发展，陆峥.新型抗抑郁药物阿戈美拉汀的研究进展[J].世界临床药物，2012，33（7）：20-21.
[11]	den Boer JA，Bosker FJ，Meesters Y.Clinical efficacy of Agomelatine in depression：the evidence[J].Int Clin Psychopharmacol，2006，21（Suppl 1）：21-24.
[12]	朱紫青，张明园.第3 代抗精神病药阿立哌唑研究进展[J].中国医院用药评价与分析，2005，5（2）：121-123.
[13]	Dunn RT，Stan VA，Chriki LS，et al.A prospective，openlabel study of Aripiprazole mono-and adjunctive treatment in acute bipolar depression[J].J Affect Disord，2008，110（1-2）：70-74.
[14]	Dunlop BW，Nemeroff CB.The role of dopamine in the pathophysiology of depression[J].Arch Gen Psychiatry，2007，64（3）：327-337.
[15]	Kaneriya SH，Robbins-Welty GA，Smagula SF，et al.Predictors and moderators of remission With Aripiprazole augmentation in treatment-resistant late-life depression：an analysis of the IRL-GRey randomized clinical trial[J].JAMA Psychiatry，2016，73（4）：329-336.